Silo Pharma's QwikAgents Joins AMD AI Developer Program To Accelerate AI Platform Development

Silo Pharma, a developmental-stage biopharmaceutical company focused on developing treatments for stress-related psychiatric disorders, chronic pain, and central nervous system (CNS) diseases, has announced that its wholly owned subsidiary, QwikAgents, has been accepted into Advanced Micro Devices' (AMD) AI Developer Program. The company believes this milestone will strengthen the development of its artificial intelligence platform by providing access to advanced AI tools, cloud computing resources, technical training, and a global community of AI developers.

Through the AMD AI Developer Program, QwikAgents will receive AMD Developer Cloud credits along with access to AI development software, technical support, educational resources, and collaboration opportunities. These resources are designed to help developers build, test, optimize, and deploy AI-powered applications more efficiently while accelerating innovation across a variety of AI use cases.

Eric Weisblum, Chief Executive Officer of Silo Pharma, said joining the AMD AI Developer Program represents an important step in advancing the QwikAgents platform. He explained that access to AMD's AI infrastructure and development ecosystem is expected to accelerate the company's ability to develop, train, test, optimize, and deploy AI agents across multiple applications.

According to Weisblum, the collaboration aligns with QwikAgents' long-term goal of making advanced AI agents more accessible not only for large enterprises but also for individual users, software developers, startups, and small businesses. He added that the platform is being designed to deliver affordable AI tools that are easy to deploy while incorporating practical controls to support safer, more manageable, and reliable AI usage.

QwikAgents is currently developing a next-generation AI agent platform that aims to provide dedicated and persistent AI agents for a broad range of users. The platform is being designed to allow customers to deploy both customizable blank AI agents and specialized agents built for specific tasks. Planned applications include research, content creation, scheduling, software development, browser automation, and workflow automation across personal and business environments.

The company expects the platform to offer entry-level subscription plans starting at $14 per month while also providing scalable infrastructure capable of supporting more advanced enterprise workloads. QwikAgents is being built with several advanced capabilities, including persistent memory that allows AI agents to retain information over time, dedicated computing infrastructure, intelligent model routing to improve efficiency, encrypted backup systems, and a simplified deployment process for users with varying technical experience.

Silo Pharma said participation in the AMD AI Developer Program is expected to support several aspects of the platform's ongoing development, including AI model hosting, workload testing, performance optimization, benchmarking, and the potential training of AI models as new capabilities are added. The company believes these resources will help improve the platform's overall performance, enhance the reliability of its AI agents, and support the scalable deployment of autonomous AI systems capable of reasoning, completing tasks, and managing complex workflows with minimal human intervention.

As QwikAgents continues expanding its platform, Silo Pharma expects the collaboration with AMD to play an important role in supporting both consumer and enterprise AI applications while accelerating the development of practical, accessible, and scalable AI agent technology.